Dave M. Johnson

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

Richard R. Furman, Jeff P. Sharman, Steven Coutré et al. · New England Journal of Medicine · 2014 · 1.7K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

Jennifer R. Brown, John C. Byrd, Steven Coutré et al. · Blood · 2014 · 584 citations · Full text

Medicine, Oncology, Pharmacology +14

Stability of Self-Assembled Monolayers on Titanium and Gold

Gopinath Mani, Dave M. Johnson, D. Marton et al. · Langmuir · 2008 · 152 citations

Natural Sciences, Chemistry, Materials Science +17

Drug delivery from gold and titanium surfaces using self-assembled monolayers

Gopinath Mani, Dave M. Johnson, D. Marton et al. · Biomaterials · 2008 · 99 citations

Natural Sciences, Materials Science, Pharmaceutics +16

Combinations of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kdelta) Inhibitor GS–1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Results From a Phase I Study

Steven Coutré, John P. Leonard, Richard R. Furman et al. · Blood · 2012 · 36 citations

Medicine, Pharmacology, Pharmacotherapy +15